HBOT showed improvement in Alzheimer's Disease

January 24, 2019

New Orleans, LA - Dr. Paul Harch, Clinical Professor and Director of Hyperbaric Medicine at LSU Health New Orleans School of Medicine, and Dr. Edward Fogarty, Chairman of Radiology at the University of North Dakota School of Medicine, report the first PET scan-documented case of improvement in brain metabolism in Alzheimer's disease in a patient treated with hyperbaric oxygen therapy (HBOT). The report, published in the current issue of the peer-reviewed journal Medical Gas Research, is available at http://www.medgasres.com/article.asp?issn=2045-9912;year=2018;volume=8;issue=4;spage=181;epage=184;aulast=Harch.

The authors report the case of a 58-year-old female who had experienced five years of cognitive decline, which began accelerating rapidly. Single photon emission computed tomography (SPECT) suggested Alzheimer's disease. The diagnosis was confirmed by 18Fluorodeoxyglucose (18FDG) positron emission tomography (PET) brain imaging, which revealed global and typical metabolic deficits in Alzheimer's.

The patient underwent a total of 40 HBOT treatments - five days a week over 66 days. Each treatment consisted of 1.15 atmosphere absolute/50 minutes total treatment time. After 21 treatments, the patient reported increased energy and level of activity, better mood and ability to perform daily living activities as well as work crossword puzzles. After 40 treatments, she reported increased memory and concentration, sleep, conversation, appetite, ability to use the computer, more good days (5/7) than bad days, resolved anxiety, and decreased disorientation and frustration. Tremor, deep knee bend, tandem gain, and motor speed were also improved. Repeat 18FDG PET imaging one month post-HBOT showed global 6.5-38% improvement in brain metabolism.

"We demonstrated the largest improvement in brain metabolism of any therapy for Alzheimer's disease," notes Dr. Harch. "HBOT in this patient may be the first treatment not only to halt, but temporarily reverse disease progression in Alzheimer's disease."

The report also contains video imaging, including unique rotating PET 3D Surface Reconstructions, which allow the lay person to easily see the improvements in brain function.

"PET imaging is used around the world as a biomarker in oncology and cardiology to assay responses to therapy," says Dr. Fogarty. "We now have an irrefutable biomarker system that this intervention has promise where no other real hope for recovery of dementia has ever existed before."

The physicians report that two months post-HBOT, the patient felt a recurrence in her symptoms. She was retreated over the next 20 months with 56 HBOTs (total 96) at the same dose, supplemental oxygen, and medications with stability of her symptoms and Folstein Mini-Mental Status exam.

According to the National Institutes of Health, "Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. It is the most common cause of dementia in older adults. Alzheimer's disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disorder may rank third, just behind heart disease and cancer, as a cause of death for older people."

The authors note that four pathological processes have been identified and primary treatment is with acetylcholinesterase inhibitors or the N-methyl-D-aspartate receptor antagonist memantine, which have been shown to have a positive impact on Alzheimer's disease progression with no significant disease-modifying effects.

HBOT is an epigenetic modulation of gene expression and suppression to treat wounds and disease pathophysiology, particularly inflammation. HBOT targets all four of the pathological processes of AD by affecting the microcirculation; mitochondrial dysfunction, and biogenesis; reducing amyloid burden and tau phosphorylation; controlling oxidative stress; and reducing inflammation.

The first successful HBOT-treated case of Alzheimer's disease was published in 2001. The present case report is the first patient in a series of 11 HBOT-treated patients with Alzheimer's disease whose symptomatic improvement is documented with 18fluorodeoxyglucose positron emission tomography (18FDG PET). "Our results suggest the possibility of treating Alzheimer's disease long-term with HBOT and pharmacotherapy," concludes Harch.
-end-
LSU Health Sciences Center New Orleans educates Louisiana's health care professionals. The state's flagship health sciences university, LSU Health New Orleans includes a School of Medicine, the state's only School of Dentistry, Louisiana's only public School of Public Health, and Schools of Allied Health Professions, Nursing, and Graduate Studies. LSU Health New Orleans faculty take care of patients in public and private hospitals and clinics throughout the region. In the vanguard of biosciences research in a number of areas in a worldwide arena, the LSU Health New Orleans research enterprise generates jobs and enormous economic impact. LSU Health New Orleans faculty have made lifesaving discoveries and continue to work to prevent, advance treatment, or cure disease. To learn more, visit http://www.lsuhsc.edu, http://www.twitter.com/LSUHealthNO, or http://www.facebook.com/LSUHSC.

Louisiana State University Health Sciences Center

Related Positron Emission Tomography Articles from Brightsurf:

Single photon emission from isolated monolayer islands of InGaN
Single photon emitters are essential devices for the realization of future optical quantum technologies including optical quantum computing and quantum key distribution.

Corona-induced CO2 emission reductions are not yet detectable in the atmosphere
The impact of the corona pandemic will reduce worldwide carbon dioxide emissions by up to eight percent in 2020.

Dynamic full-field optical coherence tomography: 3D live-imaging of retinal organoids
Optical coherence tomography offers astounding opportunities to image the complex structure of living tissue but lacks functional information.

Measuring electron emission from irradiated biomolecules
Through a study published in EPJ D, researchers have successfully determined the characteristics of electron emission when high-velocity ions collide with adenine - one of the four key nucleobases of DNA.

Nondestructive positron beams probe damage, support safety advances in radiation environments
A multi-institution team has used positron beams to probe the nature of radiation effects, providing new insight into how damage is produced in iron films.

Plant roots increase carbon emission from permafrost soils
A key uncertainty in climate projections is the amount of carbon emitted by thawing permafrost in the Arctic.

Cryo-electron tomography reveals uromodulin's role in urinary tract infection protection
Free-flowing filaments of Uromodulin protect against urinary tract infections (UTIs) by duping potentially harmful bacteria to attach to their fishbone-like molecular architecture - rather than to sensitive urinary tract tissues - before being flushed out of the body during urination, researchers report.

Tomography studies of coins shed light on the history of Volga Bulgaria
Kazan Federal University, Joint Institute for Nuclear Research (Dubna, Russia), and Khalikov Institute of Archeology (Tatarstan Academy of Sciences, Kazan, Russia) are working together to study the physical properties of the coins found on the territory of former Volga Bulgaria.

Carbon emission from permafrost soils underestimated by 14%
Picture 500 million cars stacked in rows. That's how much carbon -- about 1,000 petagrams, or one billion metric tons - -is locked away in Arctic permafrost.

Carbon emission scheme 'succeeding despite low prices'
A European Union (EU) programme aimed at reducing carbon dioxide (CO2) emissions has made significant progress despite low prices in carbon markets, according to a study at the Universities of Strathclyde and Pittsburgh.

Read More: Positron Emission Tomography News and Positron Emission Tomography Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.